Key facts
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for Ocutheia
- ·The full record, as it builds
Funding rounds
No funding rounds for Ocutheia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ocutheia
Developer of therapeutics for retinal degenerative conditions intended to address metabolic dysfunction in photoreceptors. The company's platform uses an upstream molecular target with prior clinical safety, applies insights into metabolic signaling that drives retinal cell function, and focuses on preserving photoreceptors and slowing or preventing vision loss, enabling clinicians and researchers in ophthalmology to access approaches that support improved retinal health and broader therapeutic potential.
- Sector
- Healthcare
- HQ
- Okemos, MI, United States
- Founded
- 2023
- Employees
- 4
- Website
- ocutheia.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Ocutheia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ocutheia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ocutheia in its N-PORT filings yet. We sweep new filings monthly.